

## **HUMAN PAPILLOMAVIRUS VACCINE**

### **FREQUENTLY ASK INFORMATION**

- **RECOMMENDED:**
  1. Routine vaccination of females aged 11-12 years with 3 dose vaccine. The vaccine may be started as young as 9 years old.
  2. For females aged 13-26 years who have not been previously vaccinated or who have not completed the full series.
  3. Ideally, vaccine should be administered before potential exposure to HPV through sexual contact, however those who might have already been exposed to HPV should be vaccinated.
  4. Lactating women can receive HPV vaccine.
  5. HPV vaccine is administered in a 3 dose schedule. The second and third doses should be given 2 and 6 months after the first dose.
  6. The vaccine should be shaken well before administration. The dose of HPV is 0.5 mL, given IM, preferably in the deltoid muscle.
  
- **INTERRUPTED VACCINE SCHEDULES:**
  1. If the HPV vaccine schedule is interrupted, the vaccine series does not need to be restarted.
  2. If the series is interrupted after the first dose, the second dose should be given as soon as possible, and the second and third doses should be separated by an interval of at least 12 weeks.
  3. If only the third dose is delayed, it should be administered as soon as possible.
  
- **MINIMUM DOSING INTERVALS:**
  1. The minimum interval between the first and second doses of vaccine is 4 weeks.
  2. The minimum interval between the second and third doses of vaccine is 12 weeks.
  3. Inadequate doses of HPV vaccine OR doses received after a shorter-than-recommended dosing interval should be re-administered.
  
- **SIMULTANEOUS ADMINISTRATION WITH OTHER VACCINES:**
  1. Although no data exist on administration of HPV vaccine with vaccines other than hepatitis B vaccine, HPV vaccine is not a live vaccine and has no components that adversely impact safety or efficacy of other vaccinations.
  2. Administering all indicated vaccines at the same visit should be done using a different anatomic site.
  
- **VACCINATION DURING PREGNANCY IS NOT RECOMMENDED.**
  1. The vaccine has not been associated with adverse outcomes of pregnancy or adverse events in the developing fetus. However, data on vaccination during pregnancy are limited. Until additional information is available, initiation of the vaccine series should be delayed until after completion of the pregnancy.
  2. If a woman is found to be pregnant after initiating the vaccination series, the remainder of the 3-dose regimen should be delayed until after completion of the pregnancy. If a vaccine dose has been given during pregnancy, no intervention is needed. A vaccine in pregnancy registry has been established; patients and physicians should report any exposure to HPV vaccine during pregnancy to 800-986-8999.
  
- **THE VACCINE IS CONTRAINDICATED IN PERSONS WITH A HISTORY OF ALLERGIC REACTIONS TO BAKER'S YEAST.**
  
- **ALL PATIENTS SHOULD BE OBSERVED FOR 15 MINUTES AFTER RECEIVING HPV VACCINE FOR THE POSSIBILITY OF SYNCOPE.**